Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Lineage Cell Therapeutics (LCTX) Other Gross PP&E Adjustments (2016 - 2025)

Lineage Cell Therapeutics' Other Gross PP&E Adjustments history spans 15 years, with the latest figure at -$792000.0 for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 78.51% year-over-year to -$792000.0; the TTM value through Dec 2025 reached -$792000.0, up 78.51%, while the annual FY2025 figure was -$792000.0, 78.51% up from the prior year.
  • Other Gross PP&E Adjustments reached -$792000.0 in Q4 2025 per LCTX's latest filing, down from $2.4 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $3.3 million in Q1 2022 to a low of -$3.7 million in Q4 2024.
  • Average Other Gross PP&E Adjustments over 5 years is $688700.0, with a median of $922000.0 recorded in 2021.
  • The largest YoY upside for Other Gross PP&E Adjustments was 2120.39% in 2022 against a maximum downside of 495.62% in 2022.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at -$617000.0 in 2021, then tumbled by 495.62% to -$3.7 million in 2022, then surged by 44.9% to -$2.0 million in 2023, then tumbled by 81.98% to -$3.7 million in 2024, then surged by 78.51% to -$792000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Other Gross PP&E Adjustments are -$792000.0 (Q4 2025), $2.4 million (Q3 2025), and $2.8 million (Q2 2025).